{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:35:09Z","timestamp":1794576909410,"version":"4.9.1"},"reference-count":137,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1053\/j.semnuclmed.2023.07.003","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:55:58Z","timestamp":1689998158000},"page":"46-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prognostic Value of PSMA PET\/CT in Prostate Cancer"],"prefix":"10.1053","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-040X","authenticated-orcid":false,"given":"Ismaheel O.","family":"Lawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-8995","authenticated-orcid":false,"given":"Honest","family":"Ndlovu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mankgopo","family":"Kgatle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kgomotso M.G.","family":"Mokoala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-0625","authenticated-orcid":false,"given":"Mike M.","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0001","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0002","doi-asserted-by":"crossref","first-page":"C975","DOI":"10.1152\/ajpcell.00506.2004","article-title":"Is prostate-specific membrane antigen a multifunctional protein?","volume":"288","author":"Rajasekaran","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0003","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","article-title":"A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies","volume":"59","author":"O'Keefe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0004","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0005","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0006","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fonc.2018.00623","article-title":"Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis","volume":"8","author":"Hupe","year":"2018","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0007","first-page":"1445","article-title":"Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells","volume":"2","author":"Pinto","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pros.21065","article-title":"Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid","volume":"70","author":"Yao","year":"2010","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.20171052","article-title":"Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors","volume":"215","author":"Kaittanis","year":"2018","journal-title":"J Exp Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0010","doi-asserted-by":"crossref","first-page":"eaag3326","DOI":"10.1126\/scisignal.aag3326","article-title":"PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer","volume":"10","author":"Caromile","year":"2017","journal-title":"Sci Signal"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0011","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1148\/radiol.11102023","article-title":"Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET\/CT and 111In-capromab pendetide SPECT\/CT","volume":"259","author":"Schuster","year":"2011","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0012","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): A single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0013","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2967\/jnumed.122.264832","article-title":"Differences in failure-free survival after salvage radiotherapy guided by conventional imaging versus 18F-Fluciclovine PET\/CT in postprostatectomy patients: A post hoc substratification analysis of the EMPIRE-1 trial","volume":"64","author":"Lawal","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0014","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/RLU.0000000000004590","article-title":"Impact of 18 F-fluciclovine PET\/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy","volume":"48","author":"Lawal","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: A new PET tracer for imaging of prostate cancer","volume":"7","author":"Eder","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0016","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","article-title":"Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0017","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","article-title":"Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients","volume":"48","author":"Afshar-Oromieh","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0018","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0019","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00259-016-3572-5","article-title":"Detection rate of PET\/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC","volume":"44","author":"Berliner","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0020","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.121.263440","article-title":"Utility of 18F-rhPSMA-7.3 PET for imaging of primary prostate cancer and preoperative efficacy in N-staging of unfavorable intermediate- to very high-risk patients validated by histopathology","volume":"63","author":"Langbein","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0021","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-based [(18)F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0022","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0023","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0024","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0026","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0027","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JU.0000000000003493","article-title":"Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: Results from a phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"210","author":"Jani","year":"2023","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2014.03.002","article-title":"Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies","volume":"66","author":"Pokorny","year":"2014","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0029","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2214\/AJR.18.20571","article-title":"A systematic review of the existing prostate imaging reporting and data system version 2 (PI-RADSv2) literature and subset meta-analysis of PI-RADSv2 categories stratified by Gleason scores","volume":"212","author":"Barkovich","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0031","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: A systematic review and meta-analysis","volume":"5","author":"Kawada","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0032","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): A prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0033","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0034","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00259-021-05261-y","article-title":"Diagnostic performance of 68Ga-PSMA-11 PET\/MRI-guided biopsy in patients with suspected prostate cancer: A prospective single-center study","volume":"48","author":"Ferraro","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0035","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2967\/jnumed.119.235333","article-title":"68Ga-PSMA PET\/CT combined with PET\/ultrasound-guided prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsy results","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0036","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s00259-021-05355-7","article-title":"Detection of clinically significant prostate cancer with 18F-DCFPyL PET\/multiparametric MR","volume":"48","author":"Metser","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0037","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1148\/radiol.2021204093","article-title":"Diagnostic performance of 68Ga prostate-specific membrane antigen PET\/MRI compared with multiparametric MRI for detecting clinically significant prostate cancer","volume":"301","author":"Margel","year":"2021","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0038","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0039","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2214\/AJR.19.22042","article-title":"Prospective evaluation of 18F-DCFPyL PET\/CT in detection of high-risk localized prostate cancer: Comparison with mpMRI","volume":"215","author":"Gaur","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.euo.2021.02.006","article-title":"Combined utility of 68Ga-prostate-specific membrane antigen positron emission tomography\/computed tomography and multiparametric magnetic resonance imaging in predicting prostate biopsy pathology","volume":"5","author":"Kalapara","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0041","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0042","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1148\/radiol.2017152877","article-title":"What are we missing? False-negative cancers at multiparametric MR imaging of the prostate","volume":"286","author":"Borofsky","year":"2018","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0043","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.euf.2020.03.004","article-title":"Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography in primary prostate cancer diagnosis","volume":"7","author":"Lopci","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0044","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000528720","article-title":"Diagnostic performance and clinical impact of PSMA PET\/CT versus mpMRI in patients with a high suspicion of prostate cancer and previously negative biopsy: A prospective trial (PROSPET-BX)","volume":"107","author":"Lopci","year":"2023","journal-title":"Urol Int"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","article-title":"Prediction of prostate cancer risk: The role of prostate volume and digital rectal examination in the ERSPC risk calculators","volume":"61","author":"Roobol","year":"2012","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0046","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","article-title":"Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: Improving the Rotterdam European Randomized Study of screening for prostate cancer risk calculators","volume":"75","author":"Alberts","year":"2019","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0047","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.eururo.2017.03.039","article-title":"Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer-patient-tailored risk stratification can reduce unnecessary biopsies","volume":"72","author":"Radtke","year":"2017","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0048","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euros.2023.05.002","article-title":"A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron before transperineal prostate biopsy","volume":"53","author":"Kelly","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0049","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bju.15881","article-title":"The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer","volume":"131","author":"Meijer","year":"2023","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bju.15134","article-title":"Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET\/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer","volume":"127","author":"Franklin","year":"2021","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0051","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0052","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0053","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2021.05.006","article-title":"External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: An International Multicenter Study","volume":"80","author":"Meijer","year":"2021","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0054","author":"Vis","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2023.02.006","article-title":"Histopathologically validated diagnostic accuracy of PSMA-PET\/CT in the primary and secondary staging of prostate cancer and the impact of PSMA-PET\/CT on clinical management: A systematic review and meta-analysis","author":"Jeet","year":"2023","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0057","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clgc.2018.07.009","article-title":"68Ga-PSMA PET\/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: A fait accompli?","volume":"16","author":"Lengana","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0058","series-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2023","author":"Schaeffer","year":"2023"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0059","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.eururo.2023.01.024","article-title":"Prostate-specific membrane antigen positron emission tomography in the staging of newly diagnosed prostate cancer: Is more sensitivity always better?","volume":"83","author":"Varatharajan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0060","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.eururo.2015.12.010","article-title":"The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients","volume":"69","author":"Bianchi","year":"2016","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0061","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","article-title":"Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes","volume":"76","author":"Preisser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0062","doi-asserted-by":"crossref","DOI":"10.1002\/pros.24553","article-title":"Baseline PSMA-PET\/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy","author":"Du","year":"2023","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0063","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41391-021-00347-y","article-title":"Preoperative 68Ga-PSMA PET\/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection","volume":"24","author":"Dekalo","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0064","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180667","article-title":"68Ga-HBEDD PSMA-11 PET\/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery","volume":"92","author":"Nandurkar","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bju.14506","volume":"124","author":"van Leeuwen","year":"2019","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0066","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bju.15492","article-title":"Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging","volume":"129","author":"Meijer","year":"2022","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0067","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/RLU.0000000000003549","article-title":"The association of tumor burden by 18F-FDG PET\/CT and survival in vulvar carcinoma","volume":"46","author":"Mokoala","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0068","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-012-2280-z","article-title":"Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours","volume":"40","author":"Van de Wiele","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0069","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00259-017-3766-5","article-title":"The role of F-18 FDG PET\/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma","volume":"44","author":"Lawal","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0070","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1007\/s00261-020-02745-7","article-title":"Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET\/CT in newly diagnosed prostate cancer","volume":"45","author":"Zou","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0071","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222010","article-title":"A prognostic risk score for prostate cancer based on PSMA PET-derived organ-specific tumor volumes","volume":"307","author":"Seifert","year":"2023","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0072","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.3390\/jcm10173883","article-title":"Pattern of prostate cancer recurrence assessed by 68Ga-PSMA-11 PET\/CT in men treated with primary local therapy","volume":"10","author":"Lawal","year":"2021","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0073","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"68Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: Impact on salvage radiotherapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0074","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death","volume":"41","author":"Tilki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"68Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng\/ml. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0076","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2967\/jnumed.120.261886","article-title":"Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET\/CT imaging in early relapsed prostate cancer after radical therapy: A prospective multicenter study (IAEA-PSMA study)","volume":"63","author":"Cerci","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0077","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0078","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0079","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment outcomes from 68Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA After radical prostatectomy: Prognostic value of a negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0080","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-Year Freedom from progression after 68Ga-PSMA PET\/CT-triaged management in men with biochemical recurrence after radical prostatectomy: Results of a prospective multicenter trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0081","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/cancers15010247","article-title":"The impact of PSMA-PET on oncologic control in prostate cancer patients who experienced PSA persistence or recurrence","volume":"15","author":"Bianchi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0082","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2022.04.048","article-title":"Metastasis-free survival and patterns of distant metastatic disease after prostate-specific membrane antigen positron emission tomography (PSMA-PET)-guided salvage radiation therapy in recurrent or persistent prostate cancer after prostatectomy","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0083","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2019.03.045","volume":"76","author":"Horn","year":"2019","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0084","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2018.09.009","article-title":"Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: Results from a large, multi-institutional analysis","volume":"75","author":"Fossati","year":"2019","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0085","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1007\/s00259-021-05383-3","article-title":"The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: A WARMTH multicentre study","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0086","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","article-title":"177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)","volume":"49","author":"Khreish","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0087","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0088","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0089","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0090","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0091","doi-asserted-by":"crossref","first-page":"45","DOI":"10.17159\/2078-5151\/2019\/v57n4a3107","article-title":"South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer","volume":"57","author":"Vorster","year":"2019","journal-title":"S Afr J Surg"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0092","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MOU.0000000000000685","article-title":"Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer","volume":"30","author":"Lawal","year":"2020","journal-title":"Curr Opin Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0093","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0094","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0095","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0096","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): A biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0097","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy [Abstract]","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0098","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: An international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0099","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0100","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","article-title":"Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"49","author":"Rosar","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0101","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00259-021-05434-9","article-title":"Global experience with PSMA-based alpha therapy in prostate cancer","volume":"49","author":"Sathekge","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0102","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0103","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0104","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","article-title":"Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer","volume":"49","author":"Lawal","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0105","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s00259-023-06165-9","article-title":"225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): Preliminary clinical findings","volume":"50","author":"Sathekge","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0106","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/cancers13153904","article-title":"PSMA theranostics: Science and practice","volume":"13","author":"Mokoala","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0107","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.119.229229","article-title":"Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy","volume":"61","author":"Sathekge","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0108","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2967\/jnumed.121.263618","article-title":"mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting: Response to treatment and survival analysis","volume":"63","author":"Sathekge","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0109","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-1485","article-title":"Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity","volume":"26","author":"Current","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0110","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/MNM.0000000000001464","article-title":"Efficacy of 68Ga-PSMA PET\/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients","volume":"42","author":"Oru\u00e7","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0111","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s00259-023-06123-5","article-title":"Heterogeneity of [68Ga]Ga-PSMA-11 PET\/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response","volume":"50","author":"Pan","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0112","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0113","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00259-020-04867-y","article-title":"A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET\/CT, [68Ga]Ga-NODAGAZOL PET\/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases","volume":"48","author":"Lawal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0114","doi-asserted-by":"crossref","DOI":"10.1007\/s12149-023-01854-9","article-title":"Role of volumetric parameters obtained from 68 Ga-PSMA PET\/CT and 18F-FDG PET\/CT in predicting overall survival in patients with mCRPC receiving taxane therapy","author":"G\u00fczel","year":"2023","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0115","first-page":"25","article-title":"Role of 68Ga-PSMA PET\/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment","volume":"24","author":"Can","year":"2021","journal-title":"Hell J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0116","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s12149-022-01785-x","article-title":"Role of baseline 68Ga-PSMA PET\/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment","volume":"36","author":"Telli","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0117","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0118","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2021.03.017","article-title":"Prostate-specific membrane antigen and fluciclovine transporter genes are associated with variable clinical features and molecular subtypes of primary prostate cancer","volume":"79","author":"Chu","year":"2021","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0119","doi-asserted-by":"crossref","first-page":"16708","DOI":"10.1038\/s41598-018-35058-3","article-title":"Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET\/CT imaging features in primary prostate cancer","volume":"8","author":"Kesch","year":"2018","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0120","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0121","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eururo.2023.01.022","article-title":"Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African Ancestry","volume":"84","author":"Chen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0122","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00259-017-3852-8","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate carcinoma: Preliminary results on differences between black and white South-Africans","volume":"45","author":"Sathekge","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0123","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/biomedicines10040882","article-title":"68Ga-PSMA-11 PET\/CT initial staging in Black and White South African males with ISUP Grade Group 1 and 2 prostate adenocarcinoma","volume":"10","author":"Maserumule","year":"2022","journal-title":"Biomedicines"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0124","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MNM.0000000000000791","article-title":"68Ga-PSMA-HBED-CC PET\/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: A prospective study","volume":"39","author":"Lengana","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0125","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.3390\/cancers13236026","article-title":"Additional value of PET radiomic features for the initial staging of prostate cancer: A systematic review from the literature","volume":"13","author":"Guglielmo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0126","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00259-021-05430-z","article-title":"The added value of PSMA PET\/MR radiomics for prostate cancer staging","volume":"49","author":"Solari","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0127","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00259-022-06036-9","article-title":"Predicting clinically significant prostate cancer with a deep learning approach: A multicentre retrospective study","volume":"50","author":"Zhao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13550-023-00984-5","article-title":"Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy","volume":"13","author":"Chan","year":"2023","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0129","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00259-021-05631-6","article-title":"Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET\/CT in patients with primary prostate cancer","volume":"49","author":"Yi","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0130","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00259-020-05111-3","article-title":"Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer","volume":"48","author":"Zamboglou","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0131","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00259-020-04971-z","article-title":"Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer","volume":"48","author":"Cysouw","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0132","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-023-06278-1","article-title":"Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer","author":"Muehlematter","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0133","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.3390\/cancers14194838","article-title":"68Ga-PSMA-11 PET\/CT features extracted from different radiomic zones predict response to androgen deprivation therapy in patients with advanced prostate cancer","volume":"14","author":"Tran","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0134","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1066926","article-title":"Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA","volume":"12","author":"Assadi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-022-05947-x","article-title":"Visvikis D. An EANM position paper on the application of artificial intelligence in nuclear medicine","volume":"50","author":"Hustinx","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0136","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-022-05927-1","article-title":"Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [68Ga]Ga-PSMA-11 PET\/CT images","volume":"50","author":"Kendrick","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.003_bib0137","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1007\/s00259-023-06108-4","article-title":"Automated quantification of PET\/CT skeletal tumor burden in prostate cancer using artificial intelligence: The PET index","volume":"50","author":"Lindgren Belal","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:41:54Z","timestamp":1757544114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299823000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0001299823000582"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of PSMA PET\/CT in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}